Omeros Shares Sink 21% as Europe Rejects Yartemlea, Quarterly Loss Widens
Omeros shares dropped 21% after the European Medicines Agency reaffirmed its negative opinion on narsoplimab (Yartemlea) for TA-TMA, and the company reported a widened third-quarter GAAP net loss of $57.4 million. Despite beating adjusted earnings estimates, Omeros' revenue missed expectations, leading the company to shift its near-term regulatory strategy for the drug outside Europe. However, Yartemlea's U.S. sales continue to grow, with gross revenue up 30% sequentially.
OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares
Omeros Corporation (OMER) shares dropped significantly due to a negative European regulatory opinion for its drug Yartemlea, despite strong U.S. sales growth in the third quarter. The company also announced a delay in the clinical trial for its experimental drug OMS527. Despite these setbacks, retail investor sentiment on Stocktwits remained "extremely bullish," highlighting Yartemlea's sales trajectory and a significant partnership with Novo Nordisk.
Omeros Q3 Earnings Call Highlights
Omeros reported increased third-quarter sales of its transplant complication treatment, YARTEMLEA, reaching $35.9 million, a 26% rise from the previous quarter. The company, however, posted a net loss of $57.4 million due to a non-cash adjustment tied to convertible notes, despite achieving a second consecutive quarter of positive operating cash flow. Omeros is expanding YARTEMLEA's reach across transplant centers and plans further clinical studies for YARTEMLEA and other pipeline candidates.
OMEROS ($OMER) Releases Q3 2026 Earnings
OMEROS ($OMER) reported Q3 2026 earnings, beating EPS estimates with $0.06 per share but missing revenue estimates at $35.93 million. The stock price declined by 9.17% since market close. Insider trading activity shows 12 sales and no purchases in the last 6 months, while institutional investors show mixed activity with some large additions and removals.
Omeros falls 10% despite revenue beat
Omeros Corporation reported third-quarter results that surpassed analyst expectations for both revenue and earnings, with adjusted earnings of $0.06 per share and revenue of $41.8 million. However, shares fell 10% in after-hours trading due to a widened GAAP net loss of $57.4 million, primarily driven by a non-cash loss related to derivative mark-to-market adjustments. The company's treatment, YARTEMLEA, showed strong sales growth, and Omeros generated positive operating cash flow.
Omeros (OMER) Tops Q3 EPS by 5c, Beats on Revenue
Omeros (NASDAQ: OMER) reported stronger-than-expected financial results for the third quarter, exceeding analyst estimates for both earnings per share and revenue. The company posted Q3 EPS of $0.06, outperforming the analyst consensus of $0.01 by $0.05. Additionally, Omeros reported quarterly revenue of $41.8 million, surpassing the consensus estimate of $37.27 million.
Omeros Corporation Reports Third Quarter 2026 Financial Results
Omeros Corporation reported strong financial results for the third quarter of 2026, with YARTEMLEA® gross revenue rising to $41.8 million, a 30% increase from the previous quarter. The company also achieved positive operating cash flow of $13.3 million and made strategic repurchases of its 2029 Notes and common stock, significantly reducing potential share dilution. Despite a negative opinion from the EMA for narsoplimab in TA-TMA, Omeros is expanding YARTEMLEA's market presence and advancing its diverse pipeline, including new clinical studies for ARDS and TA-TMA prevention, and progressing its OMS1029, OMS527, OncotoX-AML, and T-CAT platforms.
Omeros Corporation (OMER) stock price, news, quote and history
This article provides a detailed overview of Omeros Corporation (OMER) stock, including its current price, market data, and recent news. It highlights the company's profile as a clinical-stage biopharmaceutical company, its lead product candidates like Narsoplimab, and its financial performance, including a recent European regulatory setback. The article also includes performance comparisons against the S&P 500 and analyst insights.
Omeros Corporation (OMER) stock price, news, quote and history
Omeros Corporation (OMER) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic and orphan indications. The article provides a detailed overview of OMER's stock performance, key financial metrics, product pipeline including Narsoplimab, and analyst ratings. As of November 13, 2026, OMER's stock price was $17.59, down 2.25%, with a market cap of $1.273 billion.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) on behalf of its investors. The investigation stems from two significant drops in Omeros's stock price following negative opinions from the European Medicines Agency's CHMP regarding the company's marketing application for narsoplimab, a treatment for TA-TMA. Investors who suffered losses are encouraged to contact Pomerantz LLP.
Omeros Corporation Tokenized Stock (Coinbase) price today, OMERc to USD live price, marketcap and chart
This CoinMarketCap page provides live price, market cap, and chart information for Omeros Corporation Tokenized Stock (OMERc) on Coinbase. It notes that the token currently has a total and circulating supply of 0 OMERc. The page also features trending cryptocurrencies, popular real-world assets like tokenized stocks of major companies, and various crypto conversion rates.
Is Omeros (OMER) Undervalued Following Its November 16 Results Catalyst?
Omeros (OMER) is set to release its third-quarter 2026 results on November 16, which is a near-term catalyst. Despite recent choppy trading, with the stock down over the past month and week, Omeros has seen a significant 1-year total shareholder return of 151.09%. Simply Wall St's analyst consensus indicates Omeros is 37% undervalued with a fair value of $27.50, driven by pipeline assumptions and the expected Novo Nordisk transaction which could ease funding risks.
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
Omeros Corporation (NASDAQ: OMER) announced it will release its third-quarter 2026 financial results on Monday, November 16, 2026, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss financial results and recent developments. The call details and webcast link are available on Omeros' investor relations page.
Omeros Corporation to Announce Third Quarter Financial Results on November 16, 2026
Omeros Corporation (NASDAQ: OMER) announced it will release its third-quarter 2026 financial results on Monday, November 16, 2026, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss financial results and recent developments. Instructions for accessing the live webcast and a replay are available on Omeros' investor relations website.
Omeros faces securities fraud probe after EMA rejects drug approval twice, stock drops sharply.
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud after the European Medicines Agency (EMA) twice rejected its drug narsoplimab. The rejections, in June and October, led to a significant drop in Omeros's stock. The investigation aims to determine if the company engaged in unlawful business practices, and affected investors are encouraged to consider joining a class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating Omeros Corporation (NASDAQ: OMER) on behalf of investors for potential securities fraud. The investigation follows two significant drops in Omeros's stock price after negative opinions from the European Medicines Agency (EMA) regarding its marketing authorization application for narsoplimab. Investors are encouraged to contact Pomerantz LLP to learn more about joining the class action.
Omeros Corp (3O8.MU) Seasonal returns chart
The article provides a seasonal returns chart for Omeros Corp (3O8.MU), displaying the average monthly price return from 2016 to 2026. It shows the stock's current performance with a delayed quote from Munich, indicating a price of 16.30 EUR, down 0.40 (-2.40%). The page also includes various market data and navigation options for Yahoo Finance users.
Omeros (OMER) Stock Dropped, So What Is Driving Attention Now?
Omeros (OMER) has garnered attention due to a 46.82% share price return over the past 90 days, despite a recent 2.69% drop. The company is considered 33% undervalued, with a fair value pegged at $27.50, driven by its drug pipeline and the expected Novo Nordisk transaction which could ease debt and support growth. However, the narrative relies on timely approvals and cash inflow, with any setbacks posing risks.
Omeros grants CEO performance-based stock option award tied to share price
Omeros Corporation has granted its CEO, Gregory A. Demopulos, M.D., a performance-based stock option award for up to 500,000 shares. The vesting of these options is tied to the company's stock reaching specific price targets of $25.00, $30.00, $35.00, and $40.00 within five years, in addition to continued employment. This news follows Omeros' strong second-quarter results, which exceeded analyst expectations due to the successful launch of its drug Yartemlea.
Form 4 Omeros Corporation: Gregory A. MD Demopulos (Director, Chairman, CEO & President) For: 28 October
This article reports on a Form 4 filing for Omeros Corporation, detailing insider transactions by Gregory A. Demopulos, who serves as Director, Chairman, CEO, and President. The filing pertains to activities that occurred on October 28. The content includes the direct announcement of this Form 4.
Form 4 Omeros Corporation: Gregory A. MD Demopulos (Director, Chairman, CEO & President) For: 28 October
This article reports on a Form 4 filing for Omeros Corporation, detailing an insider transaction by Gregory A. Demopulos, who holds positions as Director, Chairman, CEO, and President. The filing pertains to activities on October 28. The article simply states the existence of this filing without providing further details about the transaction itself.
Form 8K Omeros Corporation For: 30 October By Investing.com
This article announces that Omeros Corporation (OMER) filed a Form 8K for October 30. The content primarily consists of market data and advertisements, with the core information being the SEC filing. It also includes the stock's current performance, showing a -2.69% change.
Omeros Corporation (OMER) Seasonal Returns Chart - Yahoo Finance
The Yahoo Finance page for Omeros Corporation (OMER) displays seasonal returns data, specifically the average monthly price return from 2016 to 2026. The stock closed at $18.44 with a 2.69% decrease, further dropping to $17.99 in after-hours trading. The page also provides links to various financial data points for Omeros.
Omeros faces securities fraud probe after EMA rejects drug approval twice, stock plunges.
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud after the European Medicines Agency (EMA) issued two negative opinions on its drug narsoplimab, causing significant stock drops. The EMA's rejections in June and October 2026 led to declines of 19.12% and 13.78%, respectively, prompting a class action lawsuit and impacting investor confidence. Investors affected by these events are encouraged to contact Pomerantz LLP for more information.
Omeros VP, finance & CAO Borges sells $419,000 in stock By Investing.com
David J. Borges, VP, Finance & CAO of Omeros Corp (NASDAQ:OMER), sold 20,000 shares of the company's common stock for approximately $419,000 across two days in September 2026, executed under a pre-established trading plan. Concurrently, he acquired 20,000 shares through the exercise of stock options for about $190,150. These transactions follow Omeros' strong second-quarter earnings, which exceeded expectations due to the successful launch of its drug, Yartemlea, leading to an "Overweight" rating upgrade from Cantor Fitzgerald.
Law firm investigates Omeros after stock drops on negative EMA drug approval opinions
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops. These drops occurred after the European Medicines Agency (EMA) issued negative opinions on Omeros's drug narsoplimab, leading to rejections of its marketing authorization application. The investigation could impact investor confidence and legal outcomes for Omeros.
Cantor keeps USD 22.00 target for Omeros stock
Cantor Fitzgerald has maintained its USD 22.00 price target for Omeros Corporation (OMER), suggesting a significant upside from its current trading price. The biotechnology company is expected to report its Q3 2026 results on November 12, 2026, with revenue estimates of USD 37.28 million and earnings per share of USD 0.03. Omeros currently has a market capitalization of USD 1.3 billion.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) on behalf of investors. This investigation follows two significant drops in Omeros's stock price after the European Medicines Agency (EMA) issued negative opinions on the company's marketing authorization application for narsoplimab in June and October 2026. The law firm is advising affected investors to contact them regarding a potential class action.
Form 4 Omeros Corporation: David J. Borges (VP, Finance & CAO) For: 22 September
This article reports on a Form 4 filing for Omeros Corporation (OMER) concerning David J. Borges, VP, Finance & CAO, for transactions made on September 22. Form 4 filings disclose changes in beneficial ownership of securities by company insiders. The stock price for Omeros Corporation (OMER) is noted to be up 7.37%.
Omeros Corporation (OMER) Options Chain - Yahoo Finance
The Omeros Corporation (OMER) options chain on Yahoo Finance shows real-time price data for the stock, indicating it closed at $17.49 and was trading at $17.35 after hours on October 27. However, there were no calls or puts available for the November 20, 2026 expiry date at all strike prices, suggesting a lack of active options trading for the company.
Omeros Corporation Estimates – NASDAQ:OMER
This article provides access to Omeros Corporation's financial estimates and actuals on TradingView, specifically under the NASDAQ:OMER ticker. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows for comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Omeros Corporation Estimates – LSX:A0NBFF
This article provides an overview of Omeros Corporation (A0NBFF) financials and estimates on TradingView. It directs users to explore reported financial data and analyst estimates across various statements and valuation metrics, allowing for comparison of actual results with average, high, and low estimates. The content emphasizes that it is not investment advice and encourages users to conduct their own research.
Omeros stock: MarketBeat lists November 12 earnings for Omeros stock
MarketBeat estimates that Omeros Corporation will report its third-quarter results on November 12, 2026, after market close, with an expected revenue of USD 37.28 million and consensus earnings per share of USD 0.03. The stock, trading at EUR 14.88 and USD 16.85, remains below its yearly high, despite a Cantor Fitzgerald "Overweight" rating with a USD 22.00 price target. Investors are looking to the upcoming report for a clear checkpoint after a volatile period for the biotechnology company.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating Omeros Corporation (NASDAQ: OMER) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows two negative opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) concerning Omeros's marketing authorization application for narsoplimab, which led to significant drops in the company's stock price on June 26, 2026, and October 16, 2026.
Law firm probes Omeros over stock drops after EMA rejects drug approval twice
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud after its stock fell significantly following two rejections by the European Medicines Agency (EMA) for its drug narsoplimab. The rejections occurred in June and October 2026, causing stock drops of nearly 20% and 14% respectively. The law firm is encouraging affected investors to contact them regarding potential class action participation.
Cantor keeps USD 22.00 target for Omeros stock
Cantor Fitzgerald maintained its Overweight rating and a USD 22.00 price target for Omeros Corporation (OMER). This target is 32.37% above Omeros's recent Nasdaq quote. The company reported strong second-quarter 2026 revenue of USD 28.53 million, significantly beating analyst estimates of USD 12.69 million, and adjusted earnings per share of USD 0.02 against an expected loss.
Omeros Faces Second Rejection Of Narsoplimab In Europe – OMER Stock Falls Below Key Support For First Time In Nearly 3 Months
Omeros Corporation (OMER) received a second negative opinion from the European Medicines Agency (EMA) for its Narsoplimab treatment for stem cell transplant-associated complications, causing its stock to fall below a key support level. The EMA cited insufficient evidence and a lack of a placebo group in its initial rejection in June, a decision Omeros challenged. Despite the European setback, Narsoplimab, branded Yartemlea, was approved by the FDA in December 2025 and is already generating significant commercial revenue in the U.S.
Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA
Omeros Corporation announced that the European Medicines Agency's CHMP issued a negative opinion on its marketing authorization application for narsoplimab (YARTEMLEA®) for transplant-associated thrombotic microangiopathy (TA-TMA) following re-examination. Despite FDA approval in the U.S. and significant patient-level data submitted, the CHMP maintained its negative stance. Omeros expressed disappointment but plans to pursue named-patient access in Europe and continue developing its MASP-2 franchise for other indications.
Omeros Corporation - Common Stock (Nasdaq:OMER) Stock Quote
This article provides a detailed stock quote for Omeros Corporation (OMER), including its current price, trading volume, 52-week range, and recent performance against market indices. It also lists recent news headlines related to the company, focusing on earnings reports, corporate announcements, and investor alerts regarding fraud investigations. The stock last traded at $16.20, down 13.78%, and its performance over the past year was +99.9%.
EU Panel Again Declines to Endorse Omeros Transplant Therapy
An expert panel at the European Medicines Agency (EMA) has again declined to endorse narsoplimab, Omeros Corporation’s transplant therapy. This marks the second time in 2026 that the Seattle-based biotech company has failed to secure the panel's backing for its treatment.
CHMP upholds rejection of Omeros’ narsoplimab despite US approval
The European Medicines Agency's CHMP has again rejected Omeros Corporation's narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), despite its approval in the US. The rejection was based on insufficient evidence of effectiveness, lack of a control group in the main study, and concerns about data reliability and pediatric dosing. Omeros plans to pursue named-patient access in Europe and will terminate its compassionate-use program due to increasing US commercial demand.
Omeros shares slide following European regulatory setback for Narsoplimab
Omeros Corporation's shares dropped after the European Medicines Agency's committee maintained its negative opinion on the marketing authorization for narsoplimab, a drug to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This decision contrasts with the drug's approval by the U.S. FDA, where it is marketed as YARTEMLEA. Omeros plans to terminate its European compassionate-use program but will ensure current patients complete their treatment, while continuing to develop its MASP-2 franchise for other conditions.
OMER Stock Tests Key Support After Second European Rejection For Narsoplimab
Omeros Corporation (OMER) shares dropped after European regulators rejected, for a second time, its application for Narsoplimab, a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Despite the drug's FDA approval in the U.S. and the company's strong belief in its efficacy, the European Medicines Agency (EMA) cited insufficient evidence, causing OMER stock to fall below a key support level. This second rejection comes after Omeros challenged the initial decision and provided additional patient data.
Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency
Omeros (OMER) shares experienced a decline after its Narsoplimab application was once again rejected by the European Union agency. The article, however, is a premium piece and requires a subscription to read the full content, stating that the update only includes the stock's movement in the headline and first paragraph.
Omeros Narsoplimab Application Rejected Again by EU Medicines Committee
Omeros (OMER) announced that the European Union's Committee for Medicinal Products for Human Use has once again rejected its Narsoplimab application. The article from MT Newswires is a premium piece, requiring a subscription for full access.
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros Corporation's stock fell after the European Medicines Agency (EMA) upheld its negative opinion on the marketing authorization application for narsoplimab, a drug for TA-TMA, following a re-examination. Despite the company's disappointment and submission of patient-level data, the EMA's CHMP did not provide this data to an expert group during the review. Consequently, Omeros is ending its compassionate-use program in Europe, but will continue to focus on the U.S. launch of YARTEMLEA, which received FDA approval in December 2025.
Omeros Corporation To Terminate Yartemlea Compassionate-Use Program In Europe Due To US Demand
Omeros Corporation has announced its decision to terminate the Yartemlea Compassionate-Use Program in Europe. This termination is reportedly due to high demand for the drug in the United States. The article, originating from Reuters, indicates that access to the full story requires a TradingView subscription.
European regulators reject Omeros’ TA-TMA treatment application
The European Medicines Agency's Committee for Medicinal Products for Human Use has issued a negative opinion on Omeros Corporation's marketing authorization application for narsoplimab, a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy. This decision followed a re-examination, despite the drug being approved in the U.S. under the brand name YARTEMLEA. Omeros plans to terminate its compassionate-use program in Europe due to U.S. demand but will pursue reimbursed named-patient access where permitted.
Omeros Shares Fall 4% as European Regulators Uphold Negative Opinion on Narsoplimab
Omeros Corporation (NASDAQ: OMER) saw its shares fall by 4% after the European Medicines Agency (EMA) upheld its negative opinion on the marketing authorization application for narsoplimab, a drug for TA-TMA. This decision by the CHMP follows a re-examination and contrasts with the drug's FDA approval in the United States, where it is marketed as YARTEMLEA. Omeros plans to terminate its European compassionate-use program for YARTEMLEA but will continue developing MASP-2-targeting therapies for other conditions like ARDS.
Cantor keeps USD 22.00 target for Omeros stock
Cantor Fitzgerald has maintained its Buy rating and USD 22.00 price target for Omeros (OMER) stock, citing the company's strong second-quarter revenue beat. Omeros reported Q2 revenue of USD 28.53 million, significantly surpassing the USD 12.69 million consensus, and adjusted earnings per share of USD 0.02 against an estimated loss of USD 0.27. Despite the positive analyst outlook, the stock currently trades below its 52-week high, with a Nasdaq market capitalization of USD 1.4 billion.